by The Global Antibiotic Resistance Market comprises products such as cephalosporins, fluoroquinolones, carbapenems, penicillin, and others that effectively treat bacterial infections. Antibiotics are immensely useful in treating infectious diseases and have significantly contributed to increased life expectancy. However, their overuse and misuse have resulted in numerous bacteria developing resistance to various antibiotics. This has created an urgent need to develop new drugs to combat antibiotic-resistant bacteria.
The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 BN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 to 2031.
Key players operating in the Global Antibiotic Resistance Market include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD. Growing cases of drug-resistant bacterial infections and limited pipeline of new antibiotics are fueling demand in this market. Furthermore, increasing R&D activities and collaborations between pharmaceutical companies and research institutes for developing novel drugs are expected to drive the global market expansion during the forecast period.
Key Takeaways
Key players: Key players operating in the Global Antibiotic Resistance Market Demand are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD.
Growing demand: Growing cases of drug-resistant bacterial infections and limited pipeline of new antibiotics are fueling demand in this market. According to the WHO, antibiotic resistance is one of the biggest threats to global health.
Global expansion: Furthermore, increasing R&D activities and collaborations between pharmaceutical companies and research institutes for developing novel drugs are expected to drive the global market expansion during the forecast period.
Market Key Trends
One of the major trends in the global antibiotic resistance market is the rising focus on developing new compounds that target resistant mechanisms. Researchers are working on mechanisms like efflux pump inhibitors that can counteract multidrug resistant bacteria. There is also an increased focus on developing narrow-spectrum antibiotics targeting specific pathogens as they put less evolutionary pressure on the development of resistance. Adopting prudent use guidelines for antibiotic usage in human and veterinary medicine is another trend being witnessed in this market to curb further emergence of resistance.
Porter’s Analysis
Threat of new entrants: New entrants face high costs for R&D and clinical trials to develop new antibiotics. Intellectual property also protects existing players.
Bargaining power of buyers: Individual patients have little influence over prices, while governments and institutions negotiate on behalf of populations but still face limited options for treatment.
Bargaining power of suppliers: Industry relies on specialist expertise and resources from biotech and pharmaceutical suppliers which gives them some influence over industry participants.
Threat of new substitutes: No close substitutes for antibiotics currently exist though alternatives like antibiotics are being explored.
Competitive rivalry: Competition is intense as rising resistance threatens viability of existing drugs and players race to bring new classes to market first.
Geographical Regions
North America accounts for the largest share of the global antibiotic resistance market currently in terms of value due to high healthcare expenditures and awareness. Rising prevalence of infections however mean Asia Pacific is forecast to become the fastest growing regional market during the forecast period from 2024 to 2031.
The antibiotic resistance market in Europe holds the second largest share globally, driven by strong government support for R&D funding and initiatives to promote appropriate antibiotic use. However increasing resistance poses a threat given the region’s universal healthcare coverage relying on effective treatment options remaining available.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
